Fast Five Quiz: Breast Cancer Myths

Pavani Chalasani, MD, MPH


April 20, 2021

In the arena of advanced breast cancer, resistance to endocrine therapy remains a significant clinical challenge. One suggested approach to overcome resistance is to block the overacetylation of histones. In preclinical studies, this method helped to overcome resistance to aromatase inhibitors in letrozole-resistant mouse models. However, in a phase 3 trial, the HDAC inhibitor entinostat failed to overcome resistance to endocrine therapy in HR-positive, HER2-negative advanced breast cancer.

As reported at the 2020 San Antonio Breast Cancer Symposium, the study showed no difference in response, progression-free survival, or overall survival whether entinostat was added to exemestane or exemestane was given with placebo. Experts concluded that using a different aromatase inhibitor is unlikely to change outcomes.

Read more about the treatment of breast cancer.

Follow Medscape on Facebook, Twitter, Instagram, and YouTube.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.